Accelerated approval reforms take center stage at House hearing, but a way forward remains unclear
The House Energy & Commerce committee’s health subcommittee on Thursday dug into almost two dozen different FDA- and pharma-related bills that may be tacked onto a larger bill or even the biopharma user fee bills, which have to be reauthorized before the end of September.
The massive batch of bills making their way through the House includes two critical bills that seek to reform the FDA’s accelerated approval process in different ways.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.